GLP-1 Market
LLY $1373.00 ▲ +1.4% NVO $40.66 ▲ +0.9% PFE $29.22 ▼ -0.6% VKTX $26.73 ▼ -0.4% KLRA $13.07 ▲ +0.8% GPCR $20.74 ▲ +1.9% RHHBY $59.30 ▼ -0.3%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

AZD9550

AZD9550

Company
AstraZeneca
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 9, 2026

Find a Clinical Trial Near Me

See recruiting studies for AZD9550 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07546760

    A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

    Not yet reported AstraZeneca 28 participants Est. completion 2027-02-04 4 sites Stand-alone
    Other conditions: Hepatic Impairment
    View official trial listing →
  • Completed NCT NCT05848440

    A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

    Not yet reported AstraZeneca 48 participants Est. completion 2023-11-13 1 site Stand-alone
    Other conditions: Non-alcoholic Steatohepatitis
    View official trial listing →
  • Active, not recruiting NCT NCT06151964

    A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

    Not yet reported, Not yet reported AstraZeneca 166 participants Est. completion 2027-01-29 15 sites Stand-alone
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Completed NCT NCT06862791

    A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

    Not yet reported AstraZeneca 377 participants Est. completion 2026-05-11 53 sites Stand-alone
    Other conditions: Obesity or Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07013643

    A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

    Not yet reported AstraZeneca 100 participants Est. completion 2027-07-09 2 sites Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Active, not recruiting NCT NCT07017179

    This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

    Not yet reported AstraZeneca 16 participants Est. completion 2026-10-23 3 sites Stand-alone
    Other conditions: Obesity/Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07911514

    A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234

    Not yet reported AstraZeneca 60 participants Est. completion 2027-05-04 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: AZD9550, AZD9550 solution for injection

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.